Fairvalue-Calculator Fairvalue-Calculator
EN DE

Xilio Therapeutics, Inc (XLO) Fair Value & Analysis

Healthcare · US · Market cap $59.2M

Price$8.89
Fair Value$3.90
Upside-56.1%
Quality95/100
Evidence: Low Range $2.57 – $4.87

Fair value as of: Jun 25, 2026

Analysis

Xilio Therapeutics, Inc (XLO) currently trades at $8.89, while our model-based Fair Value estimate is $3.90 — implying the stock looks roughly 56.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Xilio Therapeutics, Inc (XLO) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.90 versus a price of $8.89 — about −56% (overvalued). Model-based estimate, not financial advice.
What is the fair value of XLO?
Our 21-model fair value for Xilio Therapeutics, Inc is $3.90 (as of Jun 25, 2026), built from audited fundamentals. The current price is $8.89.
What is the quality score of XLO?
Xilio Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.